Skip to content
2000
Volume 2, Issue 1
  • ISSN: 2666-9390
  • E-ISSN: 2666-9404

Abstract

Psoriasis is a chronic inflammatory skin disorder characterised by an overactive immune response, which leads to rapid skin cell turnover. It is influenced by a combination of genetic, immunological, and environmental factors, manifesting in various forms such as plaque, guttate, pustular, and erythrodermic psoriasis, each with distinct clinical features. Recent studies highlight the role of gut dysbiosis, an imbalance in gut microbiota, as a contributing factor to psoriasis exacerbation. Disruptions in the gut microbiome can influence immune responses and inflammatory pathways, potentially worsening the condition. (), a probiotic strain, has emerged as a potential therapeutic agent among the promising interventions. Research indicates that may help restore microbiome balance, reduce systemic inflammation, and modulate immune responses in psoriasis patients. Specifically, has been shown to decrease pro-inflammatory cytokines such as IL-17 and TNF-alpha, both of which are crucial drivers of psoriasis. Moreover,

enhances gut barrier function, which may reduce systemic inflammation and improve skin lesions. Clinical studies have demonstrated improvements in the Psoriasis Area and Severity Index (PASI) scores, as well as enhancements in the quality of life for patients receiving supplementation. These findings underscore the potential of probiotics as a novel adjunctive therapy for psoriasis management, either as a standalone treatment or in combination with conventional therapies. Further studies are needed to elucidate the precise mechanisms by which modulates immune responses, determine optimal dosing regimens, and assess the potential benefits of combining probiotics with traditional psoriasis treatments. Such research could pave the way for more personalised, microbiome-based therapeutic approaches in psoriasis care.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/lff/10.2174/0126669390355811250328212849
2025-04-10
2025-09-02

  • From This Site

    /content/journals/lff/10.2174/0126669390355811250328212849
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. TripathiP. BhardwajP. Psoriasis: An autoimmune disorder.J. Drug Deliv. Ther.202010531632410.22270/jddt.v10i5.4327
     [Google Scholar]
  2. TharanikaM. BhuvanaratchaganA. ManoharanK. Clinico epidemiological study of psoriasis in a tertiary care hospital.Ann. Rom. Soc. Cell Biol.202116041618
     [Google Scholar]
  3. ShobeiriSS KhorramiM SankianM Plaque-type psoriasis inhibitors.Int Immunopharmacol2021101Pt B10832610.1016/j.intimp.2021.10832634782274
     [Google Scholar]
  4. LeungA.K.C. BarankinB. LamJ.M. LeongK.F. Childhood guttate psoriasis: An updated review.Drugs Context20231212010.7573/dic.2023‑8‑237908643
     [Google Scholar]
  5. QuinteroC.A.A. MartínezM.Á.R. Perianal psoriasis as the first manifestation of the disease.J. Coloproctol.202342345347
     [Google Scholar]
  6. SalunkeG. Review on: Alternative natural treatment for psoriasis.Int. J. Pharma Sci.20231121420
     [Google Scholar]
  7. ElkhawagaO.Y. ElletyM.M. MoftyS.O. GhanemM.S. MohamedA.O. Review of natural compounds for potential psoriasis treatment.Inflammopharmacology20233131183119810.1007/s10787‑023‑01178‑036995575
     [Google Scholar]
  8. ZafiriouE. KarampinisE. Roussaki-SchulzeA-V. In: psoriasis and exposome: Unveiling the inner and the external contributors of psoriasis diseasePsoriasis - Recent Advances in Diagnosis and Treatment IntechOpen2024
     [Google Scholar]
  9. Berna-RicoE. Perez-BootelloJ. Abbad-Jaime de AragonC. Gonzalez-CanteroA. Genetic influence on treatment response in psoriasis: New insights into personalized medicine.Int. J. Mol. Sci.20232412985010.3390/ijms2412985037372997
     [Google Scholar]
  10. ManA.M. OrăsanM.S. HoteiucO.A. Olănescu-Vaida-VoevodM.C. MocanT. Inflammation and psoriasis: A comprehensive review.Int. J. Mol. Sci.202324221609510.3390/ijms24221609538003284
     [Google Scholar]
  11. DinarelloC.A. Overview of the IL -1 family in innate inflammation and acquired immunity.Immunol. Rev.2018281182710.1111/imr.1262129247995
     [Google Scholar]
  12. BrembillaN.C. BoehnckeW.H. Revisiting the interleukin 17 family of cytokines in psoriasis: Pathogenesis and potential targets for innovative therapies.Front. Immunol.202314118645510.3389/fimmu.2023.118645537283755
     [Google Scholar]
  13. WuJ. LinS. ChenW. TNF-α contributes to sarcopenia through caspase-8/caspase-3/GSDME-mediated pyroptosis.Cell Death Discov.2023917610.1038/s41420‑023‑01365‑636823174
     [Google Scholar]
  14. CasanovaJ-L MacMickingJD NathanCF Interferon-γ and infectious diseases: Lessons and prospectsScience20243846693eadl201610.1126/science.adl2016
     [Google Scholar]
  15. BowlbyC.M. PurmessurD. DurgamS.S. Equine peripheral blood CD14+ monocyte-derived macrophage in-vitro characteristics after GM-CSF pretreatment and LPS+IFN-γ or IL-4+IL-10 differentiation.Vet. Immunol. Immunopathol.202325511053410.1016/j.vetimm.2022.11053436502640
     [Google Scholar]
  16. MrowietzU. SümbülM. GerdesS. Depression, a major comorbidity of psoriatic disease, is caused by metabolic inflammation.J. Eur. Acad. Dermatol. Venereol.20233791731173810.1111/jdv.1919237184282
     [Google Scholar]
  17. ZhaoM. ChuJ. FengS. Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review.Biomed. Pharmacother.202316411498510.1016/j.biopha.2023.11498537311282
     [Google Scholar]
  18. WenC. PanY. GaoM. WangJ. HuangK. TuP. Altered gut microbiome composition in nontreated plaque psoriasis patients.Microb. Pathog.202317510597010.1016/j.micpath.2023.10597036621696
     [Google Scholar]
  19. StecA. SikoraM. MaciejewskaM. Bacterial metabolites: A link between gut microbiota and dermatological diseases.Int. J. Mol. Sci.2023244349410.3390/ijms2404349436834904
     [Google Scholar]
  20. WuY. PengL. FengP. Gut microbes consume host energy and reciprocally provide beneficial factors to sustain a symbiotic relationship with the host.Sci. Total Environ.202390416677310.1016/j.scitotenv.2023.16677337689204
     [Google Scholar]
  21. ChaudhariA. BhartiA. DwivediM.K. Role of regulatory T cells in pathogenesis and therapeutics of psoriasis.In:Regulatory T Cells and Autoimmune Diseases.Elsevier202454157210.1016/B978‑0‑443‑13947‑5.00024‑5
     [Google Scholar]
  22. FuscoW. LorenzoM.B. CintoniM. Short-chain fatty-acid-producing bacteria: Key components of the human gut microbiota.Nutrients2023159221110.3390/nu1509221137432351
     [Google Scholar]
  23. GolpourF. Abbasi-AlaeiM. BabaeiF. Short chain fatty acids, a possible treatment option for autoimmune diseases.Biomed. Pharmacother.202316311476310.1016/j.biopha.2023.11476337105078
     [Google Scholar]
  24. GopalarathinamR. SankarR. ZhaoS.S. Role of anti-inflammatory diet and fecal microbiota transplant in psoriatic arthritis.Clin. Ther.202446758859610.1016/j.clinthera.2024.05.00538862291
     [Google Scholar]
  25. NambundungaAM Isolation and characterisation of bifidobacteria populations in infants in the Khomas region, Namibia.Degree of Master of Science in Microbiology (Food Microbiology) 2020.
     [Google Scholar]
  26. TarracchiniC. MilaniC. LugliG.A. Phylogenomic disentangling of the Bifidobacterium longum subsp. infantis taxon.Microb. Genom.20217700060910.1099/mgen.0.00060934319225
     [Google Scholar]
  27. SaturioS. NogackaA.M. SuárezM. Early-life development of the bifidobacterial community in the infant gut.Int. J. Mol. Sci.2021227338210.3390/ijms2207338233806135
     [Google Scholar]
  28. O’BrienC.E. MeierA.K. CerniogloK. Early probiotic supplementation with B. infantis in breastfed infants leads to persistent colonization at 1 year.Pediatr. Res.202291362763610.1038/s41390‑020‑01350‑033762689
     [Google Scholar]
  29. DuarR.M. HenrickB.M. CasaburiG. FreseS.A. Integrating the ecosystem services framework to define dysbiosis of the breastfed infant gut: The role of B. infantis and human milk oligosaccharides.Front. Nutr.202073310.3389/fnut.2020.0003332346537
     [Google Scholar]
  30. McFarlandL.V. KarakanT. KaratasA. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis.EClinicalMedicine20214110115410.1016/j.eclinm.2021.10115434712929
     [Google Scholar]
  31. AmaraA. Fermented food microbes and their preservative byproducts.In:Antimicrobials in food science and technology.CRC Press20243071
     [Google Scholar]
  32. HeB.L. XiongY. HuT.G. ZongM.H. WuH. Bifidobacterium spp. as functional foods: A review of current status, challenges, and strategies.Crit. Rev. Food Sci. Nutr.202363268048806510.1080/10408398.2022.205493435319324
     [Google Scholar]
  33. LenoirM. WienkeJ. Fardao-BeylerF. RoeseN. An 8-week course of Bifidobacterium longum 35624® is associated with a reduction in the symptoms of irritable bowel syndrome.Probiotics Antimicrob. Proteins202311310.1007/s12602‑023‑10151‑w37702965
     [Google Scholar]
  34. LúcioH.G. LopesR.C.S.O. GomesM.J.C. A symbiotic meal containing extruded sorghum and probiotic (Bifidobacterium longum) ameliorated intestinal health markers in individuals with chronic kidney disease: A secondary analysis of a subsample from a previous randomized and controlled clinical trial.Nutrients20241612185210.3390/nu1612185238931207
     [Google Scholar]
  35. ChenY. WeiL. SongY. Life quality among psoriasis patients based on Dermatology Life Quality Index evaluation and its association with psoriasis severity in China:A cross-sectional study.Ann. Med.2023551223184710.1080/07853890.2023.223184737417705
     [Google Scholar]
  36. MikamiK. WatanabeN. TochioT. KimotoK. AkamaF. YamamotoK. Impact of gut microbiota on host aggression: Potential applications for therapeutic interventions early in development.Microorganisms2023114100810.3390/microorganisms1104100837110431
     [Google Scholar]
  37. ParichatP. PongsakR. Probiotics: Sources, selection and health benefits.Res. J. Biotechnol.2023185
     [Google Scholar]
  38. AlsharairiN.A. Therapeutic potential of gut microbiota and its metabolite short-chain fatty acids in neonatal necrotizing enterocolitis.Life202313256110.3390/life1302056136836917
     [Google Scholar]
  39. ZhangS. YangH. WangM. Immunomodulatory biomaterials against bacterial infections: Progress, challenges, and future perspectives.Innovation20234610050310.1016/j.xinn.2023.10050337732016
     [Google Scholar]
  40. AfsharN. AminiK. MohajeraniH. SakiS. Evaluation of probiotic bifidobacteria strains from Iranian traditional dairy products for their anti-hyperlipidemic potential.Folia Microbiol. 202469487588710.1007/s12223‑023‑01124‑138198044
     [Google Scholar]
  41. TorkamanehM. TorfehM. JourianiF.H. Investigating the crucial role of selected Bifidobacterium probiotic strains in preventing or reducing inflammation by affecting the autophagy pathway.Lett. Appl. Microbiol.20237612ovad13510.1093/lambio/ovad13538081214
     [Google Scholar]
  42. AL-Smadi K Leite-Silva VR, Filho NA, Lopes PS, Mohammed Y. Innovative approaches for maintaining and enhancing skin health and managing skin diseases through microbiome-targeted strategies.Antibiotics20231212169810.3390/antibiotics1212169838136732
     [Google Scholar]
  43. Jiraskova ZakostelskaZ. ReissZ. Tlaskalova-HogenovaH. RobF. Paradoxical reactions to anti-TNFα and anti-IL-17 treatment in psoriasis patients: Are skin and/or gut microbiota involved?Dermatol. Ther. 202313491193310.1007/s13555‑023‑00904‑436929119
     [Google Scholar]
  44. DeviM.B. SarmaH.K. MukherjeeA.K. KhanM.R. Mechanistic insights into immune-microbiota interactions and preventive role of probiotics against autoimmune diabetes mellitus.Probiotics Antimicrob. Proteins2023154983100010.1007/s12602‑023‑10087‑137171690
     [Google Scholar]
  45. WieserN.V. GhiboubM. VerseijdenC. Exploring the immunomodulatory potential of human milk: Aryl hydrocarbon receptor activation and its impact on neonatal gut health.Nutrients20241610153110.3390/nu1610153138794769
     [Google Scholar]
  46. SiddiquiA. HaiderR. AaqilS.I. Probiotic formulations and gastro-intestinal diseases in the paediatric population: A narrative review.Ann. Med. Surg. 20248652836284710.1097/MS9.000000000000200738694362
     [Google Scholar]
  47. ChenX. ChenY. StantonC. Dose–response efficacy and mechanisms of orally administered Bifidobacterium breve CCFM683 on IMQ-Induced psoriasis in mice.Nutrients2023158195210.3390/nu1508195237111171
     [Google Scholar]
  48. AguwaC. EnwerejiN. SantiagoS. Targeting dysbiosis in psoriasis, atopic dermatitis, and hidradenitis suppurativa: The gut-skin axis and microbiome-directed therapy.Clin. Dermatol.202341564064910.1016/j.clindermatol.2023.09.019
     [Google Scholar]
  49. AtabatiH. EsmaeiliS.A. SaburiE. Probiotics with ameliorating effects on the severity of skin inflammation in psoriasis: Evidence from experimental and clinical studies.J. Cell. Physiol.2020235128925893710.1002/jcp.2973732346892
     [Google Scholar]
  50. BuhașM.C. CandreaR. GavrilașL.I. Transforming psoriasis care: Probiotics and prebiotics as novel therapeutic approaches.Int. J. Mol. Sci.202324131122510.3390/ijms24131122537446403
     [Google Scholar]
  51. MoludiJ. FathollahiP. KhedmatgozarH. Probiotics supplementation improves quality of life, clinical symptoms, and inflammatory status in patients with psoriasis.J. Drugs Dermatol.202221663764410.36849/JDD.623735674759
     [Google Scholar]
  52. ZhaoQ. YuJ. ZhouH. Intestinal dysbiosis exacerbates the pathogenesis of psoriasis-like phenotype through changes in fatty acid metabolism.Signal Transduct. Target. Ther.2023814010.1038/s41392‑022‑01219‑036710269
     [Google Scholar]
  53. ThyeA.Y.K. BahY.R. LawJ.W.F. Gut–skin axis: Unravelling the connection between the gut microbiome and psoriasis.Biomedicines2022105103710.3390/biomedicines1005103735625774
     [Google Scholar]
  54. Method of treating psoriasis using an il-17 receptor antibody formulation.Patent US20180346583A12018
  55. Use of CGRP antagonist compounds for treatment of psoriasis.Patent US10668132B22020
  56. Topical compositions and methods for treating psoriasisPatent US11648256B2,2023
  57. Use of TNFα inhibitor for treatment of psoriasisPatent US9090689B12015
  58. Phototherapy dressing for treating psoriasisPatent US10058711B22018
  59. Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasisPatent JP7404256B22023
  60. Study in patients with mild to moderate psoriasis (AH-PSR-01).Patent NCT014513462011
/content/journals/lff/10.2174/0126669390355811250328212849
Loading
Probiotic Interventions in Psoriasis: The Therapeutic Promise of Bifidobacterium infantis
Lett Funct Foods 2, E26669390355811 (2025); https://doi.org/10.2174/0126669390355811250328212849
/content/journals/lff/10.2174/0126669390355811250328212849
/content/journals/lff/10.2174/0126669390355811250328212849
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): B. infantis; clinical trials; gut microbiota; immunomodulation; inflammatory skin disorders; probiotics; Psoriasis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test